Swiss drug major Novartis (NVS) Monday announced that the US Court of Appeals for the Federal Circuit or CAFC has decided to upheld the validity of the Entresto (sacubitril/valsartan) combination patent in the United States.
The company said it will work to appropriately enforce the combination patent through its pediatric exclusivity period expiring in July 2025.
Novartis added that it will continue to defend and protect all its important intellectual property and regulatory rights relating to Entresto.
There are currently no generic versions of Entresto available in the US, the firm noted.
For More Such Health News, visit rttnews.com
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.